News Articles and Montana BioScience Alliance Newsletters
A National Institutes of Health research group with extensive experience studying ebolavirus countermeasures has successfully developed a vaccine against Sudan virus (SUDV) based on the licensed Ebola virus (EBOV) vaccine.
For over 20 years Golden Helix has been a software company that innovates genetic analysis software for next-generation sequencing (NGS) – and, believing that its customers and employees are at the heart of its success, it has built a glowing reputation as the industry leader in its field.
Inimmune is a leader in the discovery and development of vaccine adjuvants with over 20 years of expertise in their safe and effective use.
The University of Montana was named a top-tier “R1” research institution last year. It was the culmination of a decades-long goal for UM, and the science surge has only gained momentum in the first six months of the 2022-23 fiscal year.
Health care is Montana’s largest industry and is projected to experience more job growth than any other industry in the state over the next eight years. However, with the State employment rate hovering around 2.6%, health care facilities are facing extreme workforce shortages. Because of this high demand for health care workers, Bitterroot Health and Bitterroot College are partnering to address these workforce issues through innovation and collaboration.
As a new year begins in Congress, the Biotechnology Innovation Organization (BIO) is carrying over many of its legislative priorities from last year.
Administrative Supplements to Promote Diversity in Research and Development Small Businesses – SBIR/STTR
Contract Pre-solicitation for R&D that will contribute toward ARPA-H mission needs and SBIR program objectives.
Updates from product development and small business programs
The wait is finally over as the Biotechnology Innovation Organization (BIO) taps John F. Crowley, a longtime leader and tireless patient advocate in the biotech industry, to fill the role of the organization’s new CEO.